(15051039), U. N. V., (15051042), A. T., (15051045), W. C., (15051048), A. D., (15051051), M. P., (15051054), K. D., . . . (15051072), L. G. L. (2025). Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Chicago-Zitierstil (17. Ausg.)(15051039), Ulka N. Vaishampayan, et al. Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 X Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. 2025.
MLA-Zitierstil (9. Ausg.)(15051039), Ulka N. Vaishampayan, et al. Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 X Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. 2025.